New Pathophysiological Insights in OAB: The Mechanisms Behind the Syndrome and the Rationale Behind the Treatment

Release Date: November 2007
Expiration Date: November 30, 2008

Faculty

William Steers, MD Speaker Hovey Dabney, Professor of Urology Chair, Department of Urology University of Virginia Health System Charlottesville, VA

David Staskin, MD Faculty Moderator Associate Professor Departments of Urology New York Presbyterian Hospital New York, NY

OAB is a debilitating syndrome that negatively impacts the quality of life of over 33 million Americans. There are different therapeutic options to help yet manage the symptoms of OAB, but there is still no "cure" for this debilitating syndrome. Researchers are still discovering neural pathways in the bladder and the urothelium that may better explain how existing therapies work and may assist in identifying targets for new therapeutic options.

These new insights into bladder functioning and its role for signaling and regulatory processes are important for clinicians understanding of how medications and other therapies target different aspects of the bladder functioning. This Urology Circle activity will review the latest discoveries in bladder pathophysiology, possible new drug targets, newer pharmacotherapy options, and possible future targets for OAB treatment.

This activity will consist of didactic lectures and panel discussions supported by slides posted on the web.

• Read the objectives and other introductory information.
  
• Listen to the audio while viewing the slides: Please note that this program was recorded, and as a result, participants will not have the opportunity to ask questions of the presenter.
• Take the post-test.
• Complete the evaluation and registration information.
• Participants who complete the post-test and evaluation will be issued a CME certificate, which may be printed at their location. A database of certificates awarded online is maintained at the Dannemiller Foundation. No additional certificate will be mailed. If you have any questions, you may contact the Dannemiller Foundation at editor@dannemiller.com. Expiration date for credit is November 30, 2008.
• This activity should take about 1 hour to complete.

• Review new and established insights into bladder urothelial functioning and its role for signaling and regulatory processes.
• Explain muscarinic receptor selectivity in the context of targeted antimuscarinic pharmacotherapy for overactive bladder

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Dannemiller Memorial Educational Foundation and The Customer Link, Inc. The Dannemiller Memorial Educational Foundation is accredited by the ACCME to provide continuing medical education for physicians.

The Dannemiller Memorial Educational Foundation designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity is designed for urologists and primary care physicians with a special interest in urology.

In accordance with the Accreditation Council for Continuing Medication Education (ACCME), the Dannemiller Memorial Educational Foundation requires that any person who is in a position to control the content of a CME activity must disclose all relevant financial relationships they have with a commercial interest. Accordingly:

Dr. Steers reported that he serves as a consultant for Astellas Pharma, US, Allergan, Inc., Dynogen Pharmaceuticals, Inc. and sanofi-aventis U.S. He also is an investigator for Astellas Pharma US, Allergan, Inc., and Pfizer, Inc.

Dr. Staskin reported that he serves as a consultant and speaker for Astellas Pharma US, Inc.; Esprit Pharma; Pfizer, Inc.; and Watson Pharmaceuticals, Inc. He also receives grant/research support from Esprit Pharma and Watson Pharmaceuticals, Inc.

The Dannemiller Memorial Educational Foundation staff that was involved in the development of this activity have no financial relationships with any commercial interests that are relevant to this activity. All staff of The Customer Link, Inc. involved in the development of this activity have no financial relationships to disclose.

Jan Graham, medical writer, has no financial relationships with any commercial interests that are relevant to this activity to disclose.

To resolve identified conflicts of interest, the educational content was fully peer-reviewed by a physician member of the Dannemiller Clinical Content Review Committee who has nothing to disclose. The resulting certified activity was found to provide educational content that is current, evidence-based, and commercially balanced.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the Dannemiller Memorial Educational Foundation, Astellas Pharma US, Inc. or The Customer Link. This material is prepared based upon a review of multiple sources of information, but it is not exhaustive of the subject matter. Therefore, healthcare professionals and other individuals should review and consider other publications and materials on the subject matter before relying solely upon the information contained within this educational activity.